VEGFA and macular retinal edema: After initiating anti-VEGF treatment, the median time to absence of VA improvement or VA-loss attributable to macular oedema was 2.30 (95% CI 2.03–2.58) years in the DMO group, 5.24 (95% CI 3.73–6.75) years in the CRVO group, and 6.16 (95% CI 5.45–6.87) years in the BRVO group (Fig. 2a).